Effects of SLCO1B1 521 T>C and APOE gene polymorphisms on lipid-lowering efficacy and adverse reactions of atorvastatin
10.12206/j.issn.1006-0111.202012013
- VernacularTitle:SLCO1B1 521 T>C和APOE基因多态性对阿托伐他汀调脂疗效及安全性的影响
- Author:
Yanhui LIU
1
;
Jing DONG
1
;
Yan LU
1
;
Man LU
1
;
Yunhe DING
1
;
Wenyan LI
1
Author Information
1. Department of Pharmacy, Shanghai Pudong New Area Gongli Hospital, Shanghai 200135, China.
- Keywords:
SLCO1B1;
APOE;
gene polymorphism;
atorvastatin;
lipid regulating agents;
adverse drug reactions
- From:
Journal of Pharmaceutical Practice
2021;39(3):245-248
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of SLCO1B1 521 T>C and APOE gene polymorphisms on the clinical efficacy and safety of atorvastatin in ischemic stroke patients with dyslipidemia. Methods 210 cases of ischemic stroke with dyslipidemia were enrolled from April 2018 to December 2018 to determine SLCO1B1 521 T>C and APOE gene polymorphisms. Patients received atorvastatin 20 mg/d orally. TC, TG, HDL-C, LDL-C levels were measured to evaluate the efficacy 3 months pre-and post- treatment. TBil, ALT, AST, CK levels were assayed with following up adverse reactions to evaluate safety. Results SLCO1B1 521 T>C genotype distribution was TT79.05%, TC19.05%, CC1.90%. E2, E3, E4 allele frequencies of APOE genes were 14.28%, 67.62%, 18.10%. Each genotype conforms to the law of Hardy-Weinberg balance. After three months of medication, there were significant differences in TC, TG, LDL-C, HDL-C changes in patients with different APOE genotypes. No obvious abnormality was found in safety index. The incidence of myalgia in SLCO1B1521 T>C mutant group was significantly higher than that in the wild group (P<0.01). Conclusion Lipid regulation of atorvastatin was affected by APOE gene polymorphism. SLCO1B1521 T>C may be associated with myalgia, the adverse reaction of atorvastatin. The detection of SLCO1B1 and APOE genotyping is helpful for individualized treatment of blood lipids and provides basis for rational use of statins in patients for drug therapy management.
